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Abstract
Background  and  objectives:  Ventricular  ﬁbrillation  occurring  in  a  patient  can  result  in  unex-
pected complications.  Here,  our  aim  is  to  present  a  case  of  ventricular  ﬁbrillation  occurring
immediately after  anesthesia  induction  with  etomidate  administration.
Case report:  A  ﬁfty-six-year-old  female  patient  with  a  pre-diagnosis  of  gallstones  was  admitted
to the  operating  room  for  laparoscopic  cholecystectomy.  The  induction  was  performed  by  eto-
midate  with  a  bolus  dose  of  0.3  mg/kg.  Severe  and  fast  adduction  appeared  in  the  patient’s  arms
immediately  after  induction.  A  tachycardia  with  wide  QRS  and  ventricular  rate  188  beat/min
was  detected  on  the  monitor.  The  rhythm  turned  to  VF  during  the  preparation  of  cardiover-
sion.  Immediately  we  performed  deﬁbrillation  to  the  patient.  Sinus  rhythm  was  obtained.  It
was  decided  to  postpone  the  operation  due  to  the  patient’s  unstable  condition.
Conclusion: In  addition  to  other  known  side  effects  of  etomidate,  very  rarely,  ventricular  tachy-
cardia and  ﬁbrillation  can  be  also  seen.  To  the  best  of  our  knowledge,  this  is  the  ﬁrst  case
regarding  etomidate  causing  VF  in  the  literature.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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Resumo
Justiﬁcativa  e  objetivos:  A  ocorrência  de  ﬁbrilac¸ão  ventricular  em  um  paciente  pode  resultar
em complicac¸ões  inesperadas.  Nosso  objetivo  é  apresentar  um  caso  de  ﬁbrilac¸ão  ventricular
que  ocorreu  após  a  induc¸ão  anestésica  com  administrac¸ão  de  etomidato.
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Relato  de  caso:  Paciente  do  sexo  feminino,  56  anos,  com  pré-diagnóstico  de  cálculos  biliares,
foi admitida  na  sala  de  cirurgia  para  colecistectomia  laparoscópica.  A  anestesia  foi  induzida
com  a  administrac¸ão  de  etomidato  com  uma  dose  em  bolus  de  0,3  mg/kg.  A  paciente  apre-
sentou  uma  grave  e  rápida  aduc¸ão  dos  brac¸os  logo  após  a  induc¸ão.  Taquicardia  com  QRS  largo
e frequência  ventricular  de  188  bpm  foram  detectadas  no  monitor.  O  ritmo  converteu-se  em
ﬁbrilac¸ão  ventricular  (FV)  durante  a  preparac¸ão  para  a  cardioversão.  A  paciente  foi  imediata-
mente submetida  a  desﬁbrilac¸ão.  O  ritmo  sinusal  foi  obtido.  Decidimos  adiar  a  cirurgia  por
causa  da  condic¸ão  de  instabilidade  da  paciente.
Conclusão:  Além  dos  efeitos  secundários  conhecidos  de  etomidato,  taquicardia  ventricular  e
ﬁbrilac¸ão,  embora  muito  raramente,  também  podem  ser  observadas.  Até  onde  sabemos,  esse
é  o  primeiro  caso  na  literatura  de  FV  causado  por  etomidato.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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entricular  ﬁbrillation  (VF)  is  a  cardiac  pathology  in  which
he ventricle  is  completely  chaotic  and  does  not  contract
ffectively. VF  can  cause  very  serious  endpoints.  Etomidate
s a  hypnotic  agent  that  has  a  stable  cardiovascular  proﬁle
nd results  in  minimal  respiratory  side  effects.  For  this  rea-
on, it  is  commonly  preferred  for  the  induction  of  anesthesia
n hemodynamically  unstable  patients.1
The  reported  side  effects  related  to  etomidate  are
yoclonus, vomiting,  pain  on  injection  site,  and  adrenocor-
ical suppression.2
In  rare  cases,  other  adverse  effects  regarding  etomidate
ave been  mentioned.  In  the  current  report,  we  aimed  to
resent a  case  in  which  VF  developed  during  induction  with
tomidate in  a  patient  underwent  laparoscopic  cholecystec-
omy due  to  gallstones.  In  the  literature,  this  is  the  ﬁrst
eport investigating  this  association.
Figure  1  Preanesth
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 ﬁfty-six-year-old  female  patient  with  a  pre-diagnosis
f gallstones  was  admitted  to  the  operating  room  for
aparoscopic cholecystectomy.  The  patient’s  history  of
ypertension with  the  irregular  use  of  an  antihyperten-
ive drug  was  known  during  the  pre-anesthesia  evaluation.
outine biochemical  and  hematological  tests  were  nor-
al. ECG  was  in  normal  sinus  rhythm  (Fig.  1),  heart  rate
as 74  beats/min,  PA  chest  X-ray  was  normal,  and  consid-
red ASA  II.  The  patient  was  monitored,  and  the  initial
rterial blood  pressure  (BP):  140/110  mmHg,  heart  rate:
18 beats/min,  presence  of  sinus  tachycardia  rhythm,  and
eripheral oxygen  saturation  (SpO2):  98%  were  detected.etic  ECG  Image.
The  induction  was  performed  by  etomidate  (ETOM˙IDATE
ipuro® B.  Braun  Melsungen  AG,  Berlin-GERMANY)  with  a
olus dose  of  0.3  mg/kg.  Severe  and  fast  adduction  appeared
n the  patient’s  arms  immediately  after  induction.  Myoclonic
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Figure  2  VT  Image.
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cFigure  3  Postex
movements  were  considered  to  be  due  to  etomidate  and  a
dose of  0.6  mg/kg  rocuronium  (Esmeron® N.V.  Organon  Oss,
Netherlands)  was  given.  At  this  time,  BP  was  150/110  mmHg,
SpO2 was  98%,  heart  rate  was  110--130  beats/min,  and  the
heart rate  increased  gradually.  A  tachycardia  with  wide
QRS and  ventricular  rate  188  beat/min  was  detected  on
the monitor  (Fig.  2).  Blood  pressure  was  seen  as  decreased
to 90/60  mmHg.  The  rhythm  turned  to  VF  during  the
preparation of  cardioversion.  Immediately  we  performed
deﬁbrillation to  the  patient  (biphasic  shock  with  200  J).
Sinus rhythm  was  obtained.  We  decided  to  give  amiodarone
to the  patient  to  avoid  recurrent  VT.
A  150  mg  of  IV  amiodarone  (Cordarone® Mefar  Istanbul,
Turkey) loading  dose  was  applied  within  15  min  and  was  fol-
lowed by  maintenance  therapy.  It  was  decided  to  postpone
the operation  due  to  the  patient’s  unstable  condition.
Anesthesia  was  maintained  with  oxygen,  air,  sevoﬂu-
rane (Sevorane® Abbott  Laboratories  Ltd.,  UK)  and  fentanyl
(Fentanyl® Janssen  N.V.,  Belgium).  Thirty-seven  minutes
after the  induction  of  anesthesia,  the  patient  started
to breathe  spontaneously  and  extubation  was  proposed.
The patient  was  extubated  and  admitted  to  the  inten-
sive care  unit  (ICU).  A  cardiology  consultation  was  made
in ICU.  On  patient  echocardiography,  Left  ventricle  (LV)
e
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ction  ECG  image.
iameters  were  normal,  systolic  function  was  adequate,
eft atrium  (LA)  dilatation  was  (4.1  cm),  1+  mitral  regur-
itation and  2--3+  tricuspid  regurgitation  were  noted,
ulmonary hypertension  was  present  (35--40  mmHg),  and
jection fraction  (EF)  was  evaluated  as  63%.  Sinus  tachy-
ardia (120  beats/min)  and  nonspeciﬁc  ST  changes  in  the
atient’s ECG  (Fig.  3)  were  found  by  the  cardiologists.  Hema-
ological, biochemical,  thyroid  function  tests  were  within
ormal limits.
The patient  was  discharged  after  three  days  following
p in  the  ICU.  Two  weeks  later,  the  patient  was  admitted  for
he laparoscopic  cholecystectomy.  The  patient  was  operated
ithout any  complication,  with  the  induction  by  thiopental,
entanyl and  rocuronium,  and  sent  home.
iscussion
uring  VF,  the  ventricle  contractions  are  completely  unsyn-
hronized and  ineffective.  The  heart  cannot  provide  an
ffective cardiac  output  (CO).  The  rhythm  is  irregular,  QRS
omplex is  invisible,  and  circulation  cannot  be  achieved
ecause of  the  lack  of  Effective  CO.  Cardiopulmonary  resus-
itation should  be  initiated  immediately.
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Encountering  unpredicted  disorders  are  common  during
nesthesia induction,  the  maintenance  of  anesthesia,  and
wakening from  anesthesia.  In  this  case,  we  reported  a
rocess of  ventricular  tachycardia  and  ﬁbrillation  occur-
ing immediately  after  the  induction  of  anesthesia  with
tomidate. The  well-known  side  effects  of  etomidate  are
yoclonus, pain  on  injection  site,  and  adrenal  suppres-
ion. The  mechanism  of  myoclonus  is  not  clear,  though
t is  a  form  of  seizure  activity.  High  doses  of  etomidate
epress cortical  activity  before  than  subcortical  activity,
nd researchers  have  proposed  that  this  is  a  disinhibition
henomenon.3,4 Subcortical  neuronal  activity  inhibitor  drugs
uch as  benzodiazepines  and  opioids  prevent  the  develop-
ent of  myoclonus.5
Etomidate  injection  has  side  effects  in  terms  of  pain  and
yoclonus because  it  is  formulated  with  propylene  glycol.6,7
owever,  an  alternate  pharmaceutical  formulation  exists  to
educe the  pain  of  injection.  In  this  new  formulation,  etomi-
ate is  dissolved  in  a  fat  emulsion  composed  of  medium  and
ong chain  triglycerides.8 In  a  study,  using  only  a  single  bolus
ose of  etomidate  cause  adrenal  dysfunction  in  aspect  of
ypocortisolemia.9 This  impaired  function  results  in  a  tran-
ient and  clinically  insigniﬁcant  effect  on  adrenal  gland.7,9
n  some  cases,  adrenal  dysfunction  can  be  very  important.
herefore practitioners  must  be  aware  of  this  information
egarding the  drug.
Case  reports  related  to  adrenal  adverse  effects  with
tomidate are  common.  However,  the  cardiovascular  side
ffects are  found  in  only  one  report  associated  with  the
rug. Etomidate  typically  does  not  alter  myocardial  con-
ractility and  cardiac  output.10 Fideler  et  al.  reported  a
ase of  thyrotoxicosis  occurring  after  applying  amiodarone
reatment to  a  patient  with  heart  failure  and  suffering
rom atrial  ﬁbrillation  for  the  ﬁrst  time.  Thyroidectomy  was
lanned when  hyperthyroidism  was  unresponsive  to  medical
reatment. The  staff  noted  decreased  blood  pressure  after
nduction with  etomidate,  sufentanil  and  rocuronium,  and
orepinephrine infusion  was  started  before  the  patient  had
F followed  by  cardiac  arrest.11 In  our  case,  the  patient’s
hyroid function  tests  were  normal  and  no  signiﬁcant  car-
iac pathology  was  detected  except  for  the  development  of
inus tachycardia  and  a  slight  rise  in  blood  pressure  prior
o induction  in  the  operating  room.  The  injection  of  etomi-
ate was  considered  to  be  the  only  probable  etiology  for  the
evelopment of  VT  and  VF.
When  etomidate  and  VF  were  investigated  using  the  FDA
dverse Event  Reporting  System  (FAERS),  a  total  of  4  VF
vents had  been  reported  for  etomidate.12
According  to  another  source,  1023  cases  of  etomidate-
elated adverse  effects  have  been  found.  Among  them,  VF
as reported  in  23  patients  (2.25%).  Of  these  cases,  72.7%
ere females,  27.3%  were  males,  22.7%  were  in  the  range
f 0--1  years  old,  13.6%  in  the  range  of  20--29  years  old,
1
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.5%  in  the  range  of  30--39  years  old,  27.3%  in  the  range  of
0--59 years  old,  31.8%  percent  over  the  age  of  60  years.  The
rugs used  in  these  patients  with  VF  were  Sufentanil  citrate,
ropofol, Fentanyl,  Rocuronium  bromide,  and  Amiodarone
CL.13
As  a  result,  it  is  suggested  that  the  development  of  VF
n this  case,  after  the  exclusion  of  the  probable  etiologies
ay be  due  to  the  induction  with  etomidate.  To  the  best
f our  knowledge,  this  is  the  ﬁrst  case  regarding  etomidate
ausing VF  in  the  literature.  We  aimed  to  report  that  fol-
owing induction  with  etomidate  VF  can  occur  in  rare  cases,
nd early  diagnosis  and  immediate  intervention  with  close
ollow-up are  required  to  achieve  positive  outcomes  in  these
atients.
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